This rule-based informatics solution pulls from the electronic health record to automate the election of an appropriate biosimilar therapy based on the patient’s insurance and hospital formulary preferences, streamlining prior authorization and approval processes. This e-tool decreased administrative burden to providers, pharmacists, and prior authorization specialists and increased biosimilar utilization by 21.9%. Guest: Sarah Hudson-DiSalle, PharmD, RPh, FACCC Assistant Director of Reimbursement Services The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute   “Using an EHR auto-selection tool that takes into consideration insurance preferences and contractual relationships to provide a proactive solution has helped our providers, our pharmacists, and our prior authorization specialists.”   Hear more about this innovation at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota.   Resources: Biosimilars Implementation Roadmap [MINI PODCAST] Ep 103: Precision Medicine: Robots, Biologics, and Advocates: Lessons from the Pharmacy Improve Oral Oncolytic Workflow and Reduce Treatment Delays with a Pharmacist Collaborative Practice Agreement Shifting Chemo Administration from Inpatient to Outpatient Setting Improves Care and Reduces Costs Reducing Revenue Loss and Patient Financial Toxicity with Pharmacy Pre-Certification and Denials Management [PODCAST] Ep 39: Biosimilars—What Patients Need to Know